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Abstract
The identification and quantitative analysis of protein-protein interactions are essential to the functional characterization of
proteins in the post-proteomics era. The methods currently available are generally time-consuming, technically
complicated, insensitive and/or semi-quantitative. The lack of simple, sensitive approaches to precisely quantify protein-
protein interactions still prevents our understanding of the functions of many proteins. Here, we develop a novel dual
luciferase reporter pull-down assay by combining a biotinylated Firefly luciferase pull-down assay with a dual luciferase
reporter assay. The biotinylated Firefly luciferase-tagged protein enables rapid and efficient isolation of a putative Renilla
luciferase-tagged binding protein from a relatively small amount of sample. Both of these proteins can be quantitatively
detected using the dual luciferase reporter assay system. Protein-protein interactions, including Fos-Jun located in the
nucleus; MAVS-TRAF3 in cytoplasm; inducible IRF3 dimerization; viral protein-regulated interactions, such as MAVS-MAVS
and MAVS-TRAF3; IRF3 dimerization; and protein interaction domain mapping, are studied using this novel assay system.
Herein, we demonstrate that this dual luciferase reporter pull-down assay enables the quantification of the relative amounts
of interacting proteins that bind to streptavidin-coupled beads for protein purification. This study provides a simple, rapid,
sensitive, and efficient approach to identify and quantify relative protein-protein interactions. Importantly, the dual
luciferase reporter pull-down method will facilitate the functional determination of proteins.
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Introduction
Physical protein-protein interactions (PPIs) constitute a major
mechanism for the regulation of many essential cellular and
immunological functions, making PPIs essential components of
biological systems. The high specificity and sensitivity of biological
regulatory mechanisms depend on selective and dynamic PPI-
mediated cellular responses to different stimuli. The reactions of
cellular PPIs to environmental stimuli are essential to the host.
However, aberrations in the patterns of PPIs for specific functions
usually result in diseases. For example, chronic infection with
hepatitis C virus (HCV) results from reduction of the dimerization
of mitochondrial antiviral signaling protein (MAVS) by HCV
nonstructural (NS) protein NS3/4A protease to levels that are too
low to mount strong enough antiviral immune responses [1], [2].
Thus, measuring PPIs involved in a specific cellular compartment
can shed light on how proteins work cooperatively in a cell.
Many methods have been developed to identify PPIs, including
biophysical, biochemical and genetic approaches [3]. Traditional
assays, such as co-immunoprecipitation and pull-down assays,
which require the expression, purification of a fusion protein and
Western blot, are technically complicated, time-consuming, costly
and non-quantitative. Other methods also enable the monitoring
of in vitro and in vivo PPIs, such as yeast two hybrid, fluorescence
resonance energy transfer, bioluminescence resonance energy
transfer, tandem affinity purification, mammalian protein-protein
interaction trap and various protein complement assays that have
recently been developed [4], [5]. The combined use of these
approaches results in the identification of thousands of potential
protein interactions. However, this process is generally time-
consuming, technically complicated, insensitive and/or semi-
quantitative. The lack of simple, sensitive approaches for the
analysis of PPIs still hinders our understanding of many biological
processes. Therefore, novel strategies are still needed to precisely
characterize the components of protein complexes in the post-
proteomics era.
Luminescence-based PPIs assays, such as luminescence-based
mammalian interactome mapping (LUMIER) and the lumines-
cence-based MBP pull-down interaction screening system (LuM-
PIS), only provide quantitative information about a Rluc-tagged
protein among interacting protein pairs [6], [7]. Fluc and Rluc are
regarded as dual luciferase reporters (DLRs), which are commonly
combined to analyze relative protein expression levels. This DLR
assay system provides a simple, rapid, sensitive, and quantitative
means for the sequential measurement of Fluc and Rluc activities
within a single sample [8]. Herein, we demonstrate that DLRs can
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26414be used in the analysis of PPIs and provide additional quantitative
information about the relative amounts of interacting proteins that
bind to beads in pull-down assays.
Results
Design and feasibility of the dual luciferase reporter pull-
down assay
For the easy and efficient analysis of PPIs, we designed a novel
dual luciferase reporter pull-down (DLR-PD) assay by combining
the biotinylated Fluc pull-down assay with the DLR assay system
(Fig. 1). A biotinylated protein pull-down assay, based on specific
biotin-streptavidin interactions, is a small-scale affinity purification
technique. The binding of biotin to streptavidin is the strongest
noncovalent interaction known in nature. The high affinity of
biotin for streptavidin allows for the simple, efficient, one-step
purification of biotinylated proteins under high-stringency condi-
tions [9].
To obtain biotinylated Fluc for the DLR-PD assay, Fluc with an
HAVI tag sequence containing both 6 x His and Avi tags was
coexpressed with bacterial biotin ligase enzyme BirA to covalently
attach biotin to a specific lysine residue of the Avi Tag [10]
(Fig. 2A). After the expression of HAVI-tagged Fluc in HEK293
cells, the biotinylation of this protein was determined by both
Western blot and pull-down assays. As shown in Fig. 2B, HAVI-
tagged Fluc was biotinylated, whereas Fluc was not. There was a
small amount of unbiotinylated Fluc on the pull-down beads,
representing nonspecific binding. The activity of the remaining
Fluc in the cell lysate was quantitatively measured using the DLR
assay after purification with Streptavidin MagneSphere Paramag-
netic Particles (SA-PMPs). The Fluc activity of biotinylated HAVI-
Fluc and nonbiotinylated Fluc were approximately 75% and 25%
depleted, respectively (Fig. 2C). These data suggest that at least
50% of HAVI-Fluc was specifically bound to the beads if the
nonspecific binding of HAVI-Fluc and Fluc are equal. However,
when Fluc activity was directly measured on beads, only
approximately 3.5% of the Fluc activity of HAVI-Fluc was
detected on the beads (Fig. 2D). Notably, the nonspecific binding
of unbiotinylated Fluc was significantly reduced after washing
when Fluc activity was directly measured on beads (Fig. 2D).
Therefore, Fluc activity was directly measured on beads instead of
using the supernatant in subsequent experiments. These results
suggest that biotinylated HAVI-Fluc fusion proteins can bind
specifically to SA-PMPs beads. Importantly, the Fluc activity of the
binding proteins can be quantitatively determined. To attenuate
the effect of transfection variations on the amount of Fluc or Rluc
bound to beads, the percentage of Fluc or Rluc activity of beads to
cell lysate was used in all the experiments, which equals Fluc or
Rluc activity on the beads divided by the Fluc or Rluc activity of
the same amount of cell lysate used in the pull-down assays.
The lack of interactions between Fluc and Rluc is one of the
most important prerequisites for the DLR-PD assay to work. To
determine whether Fluc interacted with Rluc, the activity of both
Rluc and Fluc on SA-PMP beads was measured. Rluc did not bind
to co-expressed HAVI-Fluc after the pull-down assay was
performed, nor did Fluc bind to HAVI-Rluc (Fig. 2E,2F).
Moreover, the Rluc-Fluc fusion protein was observed to not bind
HAVI-Fluc or HAVI-Rluc (Fig. 2F). These results indicate that
there are no interactions between Fluc and Rluc. Furthermore,
neither Fluc nor Rluc form dimers, making the DLR-PD assay
theoretically feasible.
Establishment of the DLR-PD assay using the Jun-Fos
protein pair
Human Jun and Fos form a heterodimeric transcription factor.
Notably, these proteins strongly interact in the cellular nucleus via
their basic leucine zipper regions, making human Jun and Fos
classic model protein pairs for the development of novel PPI assays
[7], [11]. To establish DLR-PD assays for the analysis of PPIs,
biotinylated Fluc tag and Rluc tag were fused to the basic leucine
zipper regions of Jun and Fos, respectively, through a flexible
linker 4x(G4S). When the DLR-PD assay was carried out to
analyze the interaction between Jun and Fos, the percentage of
Rluc on beads to the HAVI-Fluc-bJun and co-expressed Rluc-
bFos lysate used to identify PPIs was approximately 4.0%
(Fig. 3A), which is more than 80-fold the percentage for the
other three negative controls (P,0.05) and well above the cutoff
value of 3-fold for positive PPIs in the original LUMIER assays
using Rluc-tagged protein [6]. These data suggest that HAVI-
Fluc-bJun interacts with Rluc-bFos, which is consistent with the
results obtained from the traditional pull-down assay (Fig. 3B).
Because bJun and bFos interact in the cellular nucleus, the DLR-
PD assay is suitable for the analysis of PPIs in the nucleus [11].
In these experiments, the activity ratio of Rluc to Fluc (Rluc/
Fluc) on the beads determined by the DLR-PD assay was used to
indicate the relative amount of interacting proteins that bind to the
beads. The activity ratio of Rluc/Fluc of Rluc-bFos to HAVI-Fluc-
bJun on the beads is approximately 1.7:1. To determine how the
DLR-PD assay could be used to quantify the relative molar ratio of
interacting proteins that bind to the beads based on the activity
ratio of Rluc/Fluc on the beads, Rluc-Fluc and HAVI-Fluc-Rluc
fusion molecules were used as controls. Although the molar ratio
of Rluc/Fluc was 1:1 for both proteins, the activity ratio of Rluc/
Fluc of both proteins from the cell lysate was approximately 13:1,
and the activity ratio of Rluc/Fluc of HAVI-Fluc-Rluc on the
beads was approximately 17:1 (Fig. 3C). Therefore, the molar
ratio of Rluc-bFos to HAVI-Fluc-bJun binding to the beads should
be approximately 0.1:1 when the activity ratio of Rluc/Fluc on the
Figure 1. Design of the DLR-PD assay for the quantitative
analysis of PPIs. Schematic diagram of the DLR-PD assay. Quantitative
PPIs can be measured after the pull down of biotinylated Fluc-tagged
prey proteins using SA-PMPs and bioluminescence detection of the
biotinylated Fluc-tagged prey and Rluc-tagged bait proteins bound to
the beads, respectively. SA, Streptavidin.
doi:10.1371/journal.pone.0026414.g001
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PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26414Figure 2. Feasibility of the DLR-PD assay. (A) Scheme for biotinylating the Fluc fusion protein by BirA biotin ligase and Rluc fusion protein in
Fig. 1. The sequence of 6xHis and 15-aa Avi tag fused to the N-terminus of Fluc is shown. The asterisk indicates the lysine residue that is specifically
biotinylated by BirA. The sequence of the Flag tag fused to the C-terminus of Rluc is shown. MCS, multiple clone sites; Pcmv, human cytomegalovirus
(CMV) immediate-early gene promoter; IRES, internal ribosomal entry site. (B) Western blot analysis for the expression of biotinylated Fluc in HEK293
cells transfected with either a HAVI-Fluc or Fluc expression vector (Left). Biotinylated Fluc was detected by Western blot after a pull-down assay was
performed on the cell lysate of HEK293 cells transfected with HAVI-Fluc and Fluc (Right). A three-fold addition of the cell lysate and SA-PMPs (100 ml)
were used in the pull-down assay. The protein was eluted by boiling the beads after binding. The same membrane was probed with either anti-Fluc
antibodies or streptavidin conjugated horseradish peroxidase (SA-HRP). (C) The bead depletion efficiency of Fluc indicates the depleted bead Fluc
activity ratio compared with the lysate. This value was calculated by dividing depleted Fluc activity of the beads by the Fluc activity of the same
amount of lysate used for the pull down. HEK293 cells were transfected with HAVI-Fluc or Fluc expression vectors. A pull-down assay was performed
using SA-PMPs, and the Fluc activity of the lysate and the activity of the remaining Fluc in the lysate after pull down were measured. The depleted
Fluc activity of the beads was equal to the Fluc activity of lysate minus the activity of the remaining Fluc of the lysate after the binding to the beads.
(D) Percentage of Fluc on the beads compared with the lysate after pull down using SA-PMPs. This value was calculated by dividing Fluc activity
measured on the beads by the Fluc activity in the same amount of lysate used for pull down. HEK293 cells were transfected with HAVI-Fluc or Fluc
expression vectors. The pull-down assay was performed using SA-PMPs, and the Fluc activity on the beads and in the cell lysate was measured. (E)
Schematic diagram of Rluc-Fluc and HAVI-Fluc-Rluc fusion expression constructs (Upper). Western blots of assayed protein expression in HEK293 cells
transfected with HAVI-Fluc, HAVI-Rluc, HAVI-Fluc-Rluc, Fluc, Rluc-Fluc and Rluc-Flag expression vectors. The thick arrow indicates the endogenous
biotinylated proteins (Down). SA-HRP, streptavidin conjugated horseradish peroxidase. (F) HEK293 cells were transfected or co-transfected with the
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allows us to determine the relative molar ratio of interacting
proteins that bind to SA-PMP beads. However, this molar ratio
only reflects the fusion proteins that bind to the beads and may not
relate to the native Fos-Jun interaction, which presumably is 1:1.
Therefore, normalization using Rluc-Fluc and HAVI-Fluc-Rluc
controls was not included in later experiments.
Analysis of the dimerization of interferon regulation
factor 3 using the DLR-PD assay.
Quantitative analyses of PPIs in signaling pathways can
contribute greatly to our understanding of protein functions and
regulation mechanisms. Interferon (IFN) regulatory factor 3 (IRF3)
is a master transcription factor for antiviral immune responses. In
unstimulated cells, an IRF3 monomer is present in an inactive
cytoplasmic form. Viral infection or other stimulation induces
phosphorylation of IRF3 and the formation of IRF3 homodimers,
leading to the activation of innate antiviral responses [12].
Therefore, IRF3 dimerization is one of the most important
indicators of the activation of innate immune responses.
To relatively quantify IRF3 dimerization via the DLR-PD
assay, IRF3 was fused with a biotinylated Fluc tag and a Rluc tag.
Even though HAVI-Fluc-IRF3 was co-overexpressed with Rluc-
IRF3 in HEK293 cells, the percentage of Rluc on beads compared
with the cell lysate was close to that of three negative controls
(P.0.05)(Fig. 4A). These data suggest that IRF3 does not
dimerize without stimulation.
In contrast, when both HAVI-Fluc-IRF3 and Rluc-IRF3 were
co-overexpressed with MAVS, a critical upstream adaptor in IRF3
activation signaling, the amount of Rluc-IRF3 that bound to the
beads increased in a MAVS dose-dependent manner after a pull-
down assay of HAVI-Fluc-IRF3 with SA-PMPs was performed.
The percentage of Rluc on the beads compared with the cell lysate
increased approximately 27-fold when HEK293 cells were
transfected with only 10 ng of the MAVS vector compared with
the negative control (P,0.05) (Fig. 4B). This percentage is much
higher than the cutoff value of 3-fold for positive PPIs [6].
Therefore, the dimerization of IRF3, which was stimulated with a
small amount of the MAVS expression vector, was observed using
the DLR-PD assay. The activity ratio of Rluc/Fluc in interacting
Rluc-IRF3 and HAVI-Fluc-IRF3 on the beads increased 75-fold,
from 0.01:1 to 0.75:1 when the amount of transfected MAVS
increased from 10 ng to 100 ng (P,0.05) (Fig. 4B). The
formation of a saturation curve based on the transfection of
MAVS in HEK293 cells suggested that overexpressed MAVS
induced IRF3 dimerization. When HAVI-Fluc-IRF3 or HAVI-
Fluc was co-transfected with MAVS with an increasing amount of
Rluc-IRF3 in HEK293 cells, the Rluc/Fluc ratio on the beads of
HAVI-Fluc-IRF3 became saturated very quickly, which was much
higher than that of HAVI-Fluc (Fig. 4C). These observations
confirmed that Rluc-IRF3 interacts specifically with HAVI-Fluc-
IRF3, but not with HAVI-Fluc.
To validate the DLR-PD data, a pull-down assay detected by a
traditional Western blot was also performed. Rluc-IRF3 interacted
with HAVI-Fluc-IRF3 when HEK293 cells were co-transfected
with MAVS, but these proteins did not interact with each other
without the transfection of MAVS (Fig. 4D). Similarly, HAVI-
IRF3 interacting with Myc-IRF3 was also observed only after
stimulation with MAVS, as evidenced by the pull-down assay
(Fig. 4E). These results suggest that the DLR-PD assay enables
the identification and relative quantification of IRF3 dimerization.
IRF3 dimerization is an important indicator of IRF3 activation.
The assay to measure the activity of IRF3 regulatory element
PRDIII-I regulated reporter induced by the over-expression of
different molecules in the cytoplasmic antiviral signal pathway
[13], [14] (Fig. 5A) indicated that MDA5, MAVS, TBK1, and
IKKe induced approximately only a 2-fold IRF3 reporter
activation in HEK293 cells (Fig. 5B). In contrast, using the
established DLR-PD assay, the IRF3 dimerization ratio increased
up to a thousand-fold when some molecules, such as IKKe, were
overexpressed (Fig. 5C). Although the DLR-PD assay indicates
IRF3 dimer formation and the 4xPRDIII-I luciferase activity
reflects the activation of endogenous IRF3[15], the results of both
assays are consistent when monitoring IRF3 activation.
Using the DLR-PD assay to analyze MAVS dimerization
and inhibition by HCV NS3/4A
To determine whether the DLR-PD assay is applicable to the
analysis of membranous protein interactions, MAVS dimerization
was measured using the DLR-PD assay. MAVS is located on the
outer membrane of mitochondria, and its self-association mediates
antiviral innate immune signaling [16], [17]. When HAVI-Fluc-
MAVS was co-overexpressed with Rluc-MAVS in HEK293 cells,
the percentage of Rluc on the beads compared with the cell lysate
was 0.13%, which is at least 6-fold higher than that of three
negative controls (P,0.05) and higher than the positive PPI cutoff
value of 3-fold [6] (Fig. 6A). These data suggest that HAVI-Fluc-
MAVS interacted with Rluc-MAVS when they were co-expressed,
confirming the dimerization of MAVS. Moreover, the activity
ratio of Rluc/Fluc of Rluc-MAVS and HAVI-Fluc-MAVS on the
beads was approximately 0.28:1(Fig. 6A), providing a relative
amount of interacting HAVI-Fluc-MAVS and Rluc-MAVS.
These results indicate that the DLR-PD assay is able to
quantitatively measure the PPIs of membranous protein.
HCV NS3/4A has been shown to cleave MAVS, blocking the
dimerization of MAVS, which has been shown to be critical for
innate antiviral responses and cleavage-induced redistribution of
MAVS cellular localization [2], [15]. We also proved that HCV
NS3/4A cleaved MAVS in HEK293 cells (Fig. 6B). To
quantitatively determine how HCV NS3/4A regulated the
dimerization of MAVS, HAVI-Fluc-MAVS, Rluc-MAVS and
NS3/4A were co-expressed in HEK293 cells, and the dimerization
was measured using the DLR-PD assay. The results showed that
the activity ratio of Rluc/Fluc in interacting Rluc-MAVS and
HAVI-Fluc-MAVS on the beads decreased in an HCV NS3/4A
dose-dependent manner (Fig. 6C). Therefore, HCV NS3/4A
inhibited MAVS dimerization, which is consistent with previous
studies [2], [16], [18].
Analysis of MAVS-TRAF3 interactions and regulation by
HCV NS3/4A using the DLR-PD assay
TRAF3 has been shown to be a downstream molecule of
MAVS in the RIG-I-MAVS cytoplasmic antiviral signal pathway.
Specific interactions between MAVS-TRAF3 regulate the signal-
ing of MAVS [19]. To quantitatively measure MAVS-TRAF3
interactions, HAVI-Fluc-MAVS was co-overexpressed with Rluc-
TRAF3 in HEK293 cells, and the DLR-PD assay was performed.
indicated expression vectors. The pull-down assay was performed using SA-PMPs, and the Fluc and Rluc activity on the beads and in the cell lysate
was measured. Beads/lysate indicates that the Fluc or Rluc activity ratio of the beads to the lysate. This value was calculated by dividing the Fluc (or
Rluc) activity measured on the beads by the Fluc (or Rluc) activity in the same amount of lysate for the pull down.
doi:10.1371/journal.pone.0026414.g002
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PLoS ONE | www.plosone.org 4 October 2011 | Volume 6 | Issue 10 | e26414Figure 3. Analysis of bFos-bJun interactions in HEK293 cells. (A) HAVI-Fluc-bJun associated with Rluc-bFos when co-expressed in HEK293
cells using the DLR-PD assay. HEK293 cells were co-transfected with the indicated expression vectors (100 ng), and the DLR-PD assay was performed.
The percentage of Rluc on the beads compared with the lysate was calculated by dividing the Rluc activity on the beads by the Rluc activity in the
same amount of lysate used in the pull-down assay. The Rluc/Fluc ratio on the beads was calculated by dividing the Rluc activity by the Fluc activity
measured on the beads. (B) HAVI-Fluc-bJun association with Rluc-bFos when co-expressed in HEK293 cells using the biotinylated protein pull-down
assay. The arrow indicates endogenous biotinylated proteins. PD, pull down; SA, streptavidin; WCL, whole cell lysate. (C) The Rluc/Fluc activity ratio of
Rluc-Fluc and HAVI-Fluc-Rluc in HEK293 cell lysate (Left). The Rluc/Fluc activity ratio of HAVI-Fluc-Rluc in the cell lysate and on the beads (Right).
HEK293 cells were transfected with Rluc-Fluc and HAVI-Fluc-Rluc plasmids (100 ng), and cells were collected at 48 h post-transfection.
doi:10.1371/journal.pone.0026414.g003
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PLoS ONE | www.plosone.org 5 October 2011 | Volume 6 | Issue 10 | e26414Figure 4. Analysis of IRF3 dimerization in the innate antiviral signaling pathway in HEK293 cells. (A) HAVI-Fluc-IRF3 did not associate
with Rluc-IRF3 using the DLR-PD assay. HEK293 cells were co-transfected with the indicated expression vectors (100 ng), and the DLR-PD assay was
performed. The Fluc and Rluc activity in lysate and on the beads were measured. The ratio of Fluc and Rluc activity on the beads compared with the
cell lysate was calculated by dividing the Fluc and Rluc activity measured on the beads by the Fluc and Rluc activity of the same amount of lysate
used in the pull-down assay. The percentage of Rluc on the beads compared with the cell lysate was calculated by dividing the Rluc activity measured
on the beads by the Rluc activity of the same amount of lysate used in the pull-down assay. (B) HAVI-Fluc-IRF3 association with Rluc-IRF3 induced by
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was 1.85% (Fig. 7A), which is more than 26-fold higher than that
of three negative controls (P,0.05) and higher than the cutoff
value of 3-fold for positive PPIs [6]. These results suggest that
MAVS interacts with TRAF3. Additionally, interactions between
MAVS and TRAF3 were also confirmed by a traditional pull-
down assay (Fig. 7C). The results of the DLR-PD assay
demonstrated that the activity ratio of Rluc/Fluc to Rluc-TRAF3
and HAVI-Fluc-MAVS on the beads was approximately
2.29:1(Fig. 7A), indicating the relative amount of interacting
proteins.
Previous studies have shown that HCV NS3/4A cleaved MAVS
and inhibited the dimerization of MAVS [16], [18], but how it
regulates MAVS-TRAF3 interactions remains unclear. To
determine how HCV NS3/4A regulates these interactions, HCV
NS3/4A was cotransfected with Rluc-TRAF3 and HAVI-Fluc-
MAVS in HEK293 cells, and the DLR-PD assay was performed.
The activity ratio of Rluc/Fluc to Rluc-TRAF3 and HAVI-Fluc-
MAVS significantly decreased from 2.29:1 to 0.956:1 when the
amount of transfected HCV NS3/4A DNA increased from 10 ng
to 100 ng (Fig. 7B). These results were consistent with those from
the traditional pull-down assay (Fig. 7C), suggesting that HCV
NS3/4A resulted in a smaller amount of TRAF3 binding to the
same amount of cleaved MAVS compared with full length of
MAVS. Because the cleavage site of MAVS by HCV NS3/4A is
close to its transmembrane (TM) domain, our results also
suggested that the MAVS TM domain plays a very important
role in MAVS-TRAF3 signaling (Fig. 7C). These results
demonstrate that cleavage of MAVS by HCV NS3/4A not only
inhibits the self-association of MAVS (Fig. 6D) but also blocks the
recruitment of TRAF3 to MAVS (Fig. 7C). Therefore, HCV
NS3/4A lowers the capability of MAVS to activate its downstream
molecule TRAF3 through the cleavage of MAVS, which in turn
results in the inhibition of innate antiviral responses (Fig. 7D).
Application of the DLR-PD assay to protein interaction
domain mapping
Protein interaction domain mapping is very important for
studying PPIs. To determine whether the DLR-PD assay is
suitable for domain mapping, the domain of MAVS, which is
overexpressed eYFP-MAVS in a dose-dependent manner using the DLR-PD assay. HEK293 cells were co-transfected with HAVI-Fluc-IRF3 (100 ng),
Rluc-IRF3 (100 ng), and DNA (100 ng) containing eYFP-MAVS vector (0, 10, 50 or 100 ng) and control plasmid pcDNA3.1. The percentage of Rluc on
the beads compared with the lysate was calculated by dividing the Rluc activity of Rluc-IRF3 measured on the beads by the Rluc activity in the same
amount of lysate used in the pull-down assay. The Rluc/Fluc ratio on the beads was calculated by dividing the Rluc activity by the Fluc activity
measured on the beads. (C) HAVI-Fluc-IRF3 association with Rluc-IRF3 induced by overexpressed eYFP-MAVS in HEK293 cells using the biotinylated
protein pull-down assay. (D) Evaluation of the HAVI-IRF3 association with Myc-IRF3 induced by overexpressed eYFP-MAVS in HEK293 cells using the
biotinylated protein pull-down assay. (E) The curve of the Rluc/Fluc ratio on the beads based on the DLR-PD assay results. HEK293 cells were
transfected with eYFP-MAVS (50 ng), HAVI-Fluc-IRF3 (20 ng) or HAVI-Fluc (20 ng) and Rluc-IRF3 plasmid DNA (1, 10, 100 or 500 ng). Cells were
collected at 48 h post-transfection and subsequently used in the DLR-PD assay.
doi:10.1371/journal.pone.0026414.g004
Figure 5. Comparison of IRF3 dimerization using the DLR-PD assay and activation of the IRF3 regulatory element PRDIII-I induced
by different molecules in HEK293 cells. (A) Schematic diagram of virus-activated innate antiviral signaling pathways. (B) Activation of the IRF3
regulatory element PRDIII-I induced by different expression vectors (control pCDNA3.1, GFP2-RIG-I, Halo-MDA5, eYFP-MAVS, Myc-TRAF3, Myc-TBK1 or
Myc-IKKe) in HEK293 cells 24 h post-transfection. The IRF3 regulatory element PRDIII-I was assayed with 4xPRDIII-I-Fluc and the pRL-TK dual reporter.
After being normalized by Rluc activity, Fluc activity from different cell lysates was compared with that of control pCDNA3.1-transfected cells. (C)
Analysis of the association of HAVI-Fluc-IRF3 with Rluc-IRF3 induced by different molecules using the DLR-PD assay. HEK293 cells were co-transfected
with HAVI-Fluc-IRF3 (20 ng), Rluc-IRF3 (10 ng) and different expression vectors (100 ng of control pCDNA3.1, GFP2-RIG-I, Halo-MDA5, eYFP-MAVS,
Myc-TRAF3, Myc-TBK1 or Myc-IKKe). Subsequently, the DLR-PD assay was performed. The Rluc/Fluc ratio on the beads was calculated by dividing the
Rluc activity by the Fluc activity measured on the beads.
doi:10.1371/journal.pone.0026414.g005
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(Fig. 8A). The results indicated that the MAVS TM domain
played a more important role than the proline-rich and CARD
domains in MAVS-TRAF3 interactions (P,0.05) (Fig. 8B).
However, the molecular integrity of MAVS was critical for MAVS
and TRAF3 to interact, which is consistent with the result of the
traditional pull-down assay (Fig. 7C).
Discussion
In the present study, we describe a novel DLR-PD assay for the
relative quantification of interacting proteins that bind to beads for
pull down. The DLR-PD assay system is based on the
combination of biotinylated Fluc pull-down and DLR assays.
The biotinylated Fluc-tagged protein acts as the prey to capture a
putative binding bait protein tagged with Rluc. Unlike a Western
blot that is used for detecting the amount of interacting proteins in
a typical pull-down assay, the DLR-PD assay is used to determine
the amount of biotinylated Fluc-prey and Rluc-bait fusion protein
on the beads and in the cell lysate by measuring the activities of
Fluc and Rluc. This assay allows for the quantification of the
relative amount of purified interacting protein pairs (Fig. 3A, 4B,
6A, and 7A), which will be useful in the identification of a novel
protein that regulates PPIs in a known signaling pathway, such as
NS3/4A (Fig. 6C and 7C). Moreover, through the measurement
of the Fluc and Rluc activities of Fluc- and Rluc-tagged proteins in
the cell lysate, the expression levels of tested proteins can be
determined prior to performing the DLR-PD assay, and the results
can be used as internal controls in the DLR-PD assay. In this case,
the DLR-PD assay is superior to already available methods, such
as two-hybrid or split-luciferase systems, for determining the
expression levels of tested proteins. However, two-hybrid and split-
luciferase systems enable us to measure protein-protein interac-
tions in vivo non-invasively, which is not possible in DLR-PD
assays.
Both LUMIER and LuMPIS assays also use Rluc-tagged
proteins to determine PPIs [6], [7]. However, these assays only
provide quantitative information about the Rluc-tagged protein
among interacting protein pairs, similar to the results shown in the
left of Figs. 3A, 4B, 6A and 7A. Because Fluc-tagged proteins can
be used to determine PPIs in DLR-PD assays, the relative amount
of PPIs can be quantified as shown in the right of Figs. 3A, 4B,
6A and 7A. Furthermore, because Fluc-tagged proteins can serve
as internal controls to limit variations of the amount of prey
proteins, the result regarding IRF3 dimer analysis in the right of
Fig. 4B is more accurate than that in the left. As a result, DLR-
Figure 6. Analysis of MAVS dimerization and inhibition by HCV NS3/4A in HEK293 cells. (A) Evaluation of the HAVI-Fluc-MAVS association
with Rluc-MAVS using the DLR-PD assay. HEK293 cells were co-transfected with the indicated vectors (100 ng). The percentage of Rluc on the beads
compared with the cell lysate was calculated by dividing the Rluc activity of Rluc-MAVS on the beads with the Rluc activity in the same amount of
lysate used in the pull-down assays. The Rluc/Fluc ratio on the beads was calculated by dividing the Rluc activity by the Fluc activity measured on the
beads. (B) HAVI-MAVS was cleaved by HCV NS3/4A and detected by Western blot when coexpressed in HEK293 cells. (C) Analysis of the interactions
between HAVI-Fluc-MAVS and Rluc-MAVS inhibited by HCV NS3/4A using the DLR-PD assay. HEK293 cells were co-transfected with HAVI-Fluc-MAVS
(100 ng), Rluc-MAVS (100 ng) and DNA (100 ng) containing the NS3/4A vector (0, 10, 50 or 100 ng) and control plasmid pCI neo. The Rluc/Fluc ratio
on the beads was calculated by dividing the Rluc activity by the Fluc activity measured on the beads.
doi:10.1371/journal.pone.0026414.g006
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the LUMIER and LuMPIS methods. DLR-PD assays even allow
for the quantification of the molar ratio of purified interacting
protein pairs if suitable controls, such as Rluc-Fluc or HAVI-Fluc-
Rluc, are included (Fig. 3C). The relative molar ratio of
interacting proteins determined by the DLR-PD assay only reflects
interacting proteins that bind to the beads and may not relate to
native PPIs. For example, the molar ratio of Rluc-bFos to HAVI-
Fluc-bJun that bound to the beads was measured to be
approximately 0.1:1 based on our DLR-PD assay results
(Fig. 3A and 3C). This molar ratio is different from the native
Fos-Jun interaction, which presumably is 1:1. Furthermore, the
DLR-PD assay may not be suited to measure the affinity between
interacting proteins, as is the case with both the LUMIER and
LuMPIS methods [6], [7].
We observed that bound SA-PMPs depleted the activity of
approximately 75% of biotinylated HAVI-Fluc when the Fluc
activity value of the lysate after binding SA-PMPs was subtracted
from the Fluc activity value of the lysate prior to binding (Fig. 2C).
However, it was difficult to discriminate specific binding from
nonspecific binding because approximately 25% of unbiotinylated
Fluc was also bound to the beads. Therefore, the pull-down
efficiency of our assay is at least 50% if nonspecific binding is also
taken into consideration. When Fluc activity was directly
measured on the beads after washing and divided by the Fluc
activity of the cell lysate prior to binding, the nonspecific binding
of unbiotinylated Fluc was significantly reduced (Fig. 2D).
However, the percentage of beads bound to Fluc and Rluc
compared with the cell lysate was only approximately 5% or even
lower in most DLR-PD assays (Figs. 2D, 3A, 4A and 7A).
Figure 7. Analysis of MAVS-TRAF3 interactions and regulation by HCV NS3/4A in HEK293 cells. (A) HAVI-Fluc-MAVS was determined to
be associated with Rluc-TRAF3 using the DLR-PD assay. HEK293 cells were co-transfected with the indicated vectors. The percentage of Rluc on the
beads compared with the cell lysate was calculated by dividing the Rluc activity of Rluc-TRAF3 measured on the beads by the Rluc activity in the
same amount of lysate used in the pull-down assay. The Rluc/Fluc ratio on the beads was calculated by dividing the Rluc activity by the Fluc activity
measured on the beads. (B) Using the DLR-PD assay, the HAVI-Fluc-MAVS association with Rluc-TRAF3 was determined to be inhibited by HCV NS3/
4A in a dose-dependent manner in HEK293 cells. Cells were co-transfected with HAVI-Fluc-MAVS (100 ng), Rluc-TRAF3 (100 ng) and DNA (100 ng)
containing the NS3/4A vector (0, 10, 50 or 100 ng) and control plasmid pCI neo. The Rluc/Fluc ratio on the beads was calculated by dividing the Rluc
activity by the Fluc activity measured on the beads. (C) Biotinylated protein pull-down assay to determine the MAVS-TRAF3 interactions and
regulation by HCV NS3/4A in HEK293 cells. (D) Overexpression of HCV NS3/4A inhibited the MAVS-induced activation of the IFNb-Luc promoter after
normalization with RL-TK in HEK293 cells. The Fluc activity from different cell lysates was divided by that of cell lysates from mock transfected cells
without MAVS activation.
doi:10.1371/journal.pone.0026414.g007
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and streptavidin by washing with PBS alone, we hypothesize that
this low ratio is a result of the inhibition of the activity of Fluc and
Rluc by the magnetic beads rather than low the pull-down
efficiency of biotinylated proteins. Nevertheless, Fluc activity was
directly measured on the beads in all experiments because
nonspecific binding was significantly reduced.
It is important to use biotinylated Fluc-tagged prey proteins for
capturing putative Rluc-tagged binding bait proteins. The ratio of
Rluc/Fluc activity is approximately 12–14:1 when the molar ratio
of Rluc/Fluc is 1:1 (Fig. 3C). In addition, the value of Rluc/Fluc
increased when both Rluc and Fluc proteins bound to the beads
compared with them being in solution (Fig. 3C). These two
features increase the sensitivity of the DLR-PD assay for the
quantitative analysis of PPIs, which will be especially helpful for
the analysis of PPIs with a low ratio of Rluc/Fluc on the beads,
such as the interactions of MAVS (Fig. 6A).
Regarding the analysis of dimer formation for IRF3, the ratio of
Rluc to Fluc on the beads in Fig. 4B was extremely low. It is
possible that two HAVI-Fluc-IRF3 molecules as well as two Rluc-
IRF3 molecules interacted with each other, respectively, to form a
dimer. The Rluc/Fluc ratio on the beads reached a maximum
value and then slowly decreased when the amount of Rluc-IRF3
increased continuously, which may support the hypothesis that
two Rluc-IRF3 molecules formed a dimer (Fig. 4C). The same is
true for the analysis of MAVS dimerization in Fig. 6A. The
experiment showing the dependence of the IRF3 interaction on an
upstream regulator demonstrates that the new method is flexible
and can be adapted to different protein interactions.
In summary, a novel biochemical DLR-PD assay was established
for analysisofPPIs. ExamplesofnuclearPPIs (Fos-Jun), cytoplasmic
membranous PPIs (MAVS-MAVS, MAVS-TRAF3), inducible
PPIs (e.g., IRF3 dimerization induced by MAVS and TBK1), and
viral protein-regulated PPIs (MAVS-MAVS, MAVS-TRAF3 by
HCV NS3/4A) were studied using the DLR-PD assay. The
applications of the DLR-PD assay to analyze PPIs, such as protein
interaction domain mapping and viral protein targets in innate
antiviral signaling pathways, were explored. The DLR-PD assay
system was demonstrated to provide a simple, rapid, sensitive, and
efficient approach to analysis of PPIs and will be useful for the
functional determination of protein complexes.
Materials and Methods
Constructs
The coding sequences of genes were amplified by PCR using
Platinum Pfx DNA polymerase (Invitrogen). The primers and other
DNA sequences are listed in Table 1. The fragments were cloned
using the pEASY-Blunt Cloning Kit (Transgen) and verified by
sequencing. The EMCV IRES was amplified from the pIRES
vector (Clontech). The coding region of the birA biotin-protein
ligase gene was amplified from E. coli genomic DNA. EMCV IRES
and the birA gene were ligated using the SacII restriction site. The
EMCV IRES-driven birA gene was recloned into the SmaI and
NotI restriction sites of the mammalian cell expression vector pCI
neo (Promega). The HAVI tag sequence containing both 6 x HIS
and the Avi tags for biotinylation and multiple clone sites were
synthesized by the Augct company and cloned into the NheI and
SmaI restriction sites of pCI neo with the EMCV IRES-driven birA
gene to construct the biotinylation expression vector pHAVI. The
Fluc gene was amplified from pGL3-Basic (Promega), digested with
SalI and XhoI restriction enzymes and religated into the XhoI
restriction site of pHAVI to construct pHAVI-Fluc. The fragment
containing Rluc was amplified from pRL-TK (Promega), digested
with XhoI and XbaI restriction enzymes and cloned into the XhoI
and XbaI restriction sites of pHAVI to construct pHAVI-Rluc. The
fragment containing Rluc digested with NheI and SmaI restriction
enzymes was cloned into the XbaI and EcoRV restriction sites of
pHAVI-Fluc to construct the pHAVI-Fluc-Rluc vector. A flag tag
sequence was synthesized by the Augct Company and cloned into
the SalI and NotI restriction sites of pCI neo to construct the pCI-
Flag vector. The Rluc gene was ligated into the NheI and XhoI
restriction sites of pCI-Flag to construct the pCI-Rluc-Flag vector.
The pCI-Rluc-Fluc vector was formed by cloning the Fluc fragment
with XhoI and SmaI restriction sites into the XhoI and EcoRV
restriction sites of the pCI-Rluc-Flag vector. pCMV-Fluc was
Figure 8. Application of the DLR-PD assay to the domain mapping of the interaction of MAVS with TRAF3. (A) Western blot of HAVI-
Fluc-tagged MAVS domains and Rluc-tagged TRAF3 in HEK293 cells. (B) Domain mapping of the interaction of MAVS with TRAF3 using the DLR-PD
assay. HEK293 cells were co-transfected with Rluc-TRAF3, and the different domains of MAVS were fused with HAVI-Fluc vectors. MAVS CD, MAVS
Card domain; MAVS PD, MAVS proline-rich domain; MAVS TM, MAVS transmembrane domain. The Rluc/Fluc ratio on the beads was calculated by
dividing the Rluc activity by the Fluc activity measured on the beads.
doi:10.1371/journal.pone.0026414.g008
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pGL3-Basis vector. The pRL-CMV vector was bought from the
Promega Company. The NS3/4A sequence derived from pCon1-
FL was cloned into the EcoRI and XbaI restriction sites of pCI neo.
TRAF3, IRF3, and MAVS were cloned into the XhoI and MluI
restrictionsitesofpHAVItoconstructthepHAVI-TRAF3,pHAVI-
IRF3, and pHAVI-MAVS vectors, respectively. IRF3, MAVS,
MAVS Card (MAVS CD) and the proline-rich MAVS domain
(MAVS PD) were cloned into the XhoI and MluI restriction sites of
pHAVI-Fluc to construct the pHAVI-Fluc-IRF3, pHAVI-Fluc-
MAVS, pHAVI-Fluc-MAVSCD, and pHAVI-Fluc-MAVSPD
vectors, respectively. The MAVS TM was cloned into the MluI
and SalI restriction sites of pHAVI-Fluc to construct the pHAVI-
Fluc-MAVSTM vector. TRAF3, IRF3, and MAVS were cloned
into the XhoI and MluI restriction sites of pCI-Rluc-Flag to express
the Rluc-TRAF3-Flag, Rluc-IRF3-Flag and Rluc-MAVS-Flag
proteins, respectively. The basic leucine zipper (bZIP) regions of
Jun (225–334) and Fos (118–220) were synthesized by the Generay
Company and cloned into the XhoI and MluI restriction sites of
pHAVI-Fluc and pCI-Rluc-Flag to construct the pHAVI-Fluc-bJun
and pCI-Rluc-bFos-Flag vectors, respectively. pIFNb-Luc was
constructed by subcloning the human IFNb promoter (2281–
+20) into pTAL-Luc (Clontech) between the NheI and EcoRI
restrictionsites.pHalo-MDA5wasobtainedfromGeneCopoeiaInc.
pNFkB-Luc and pISRE-Luc were obtained from Clontech.
Reagents
Lipofectamine 2000 transfection reagent was purchased from
Invitrogen. Streptavidin MagneSphere Paramagnetic Particles
(SA-PMPs), the Dual-Luciferase Reporter Assay System and goat
polyclonal antibody to Fluc (G7451) were all obtained from
Promega. Anti-flag tagged mouse monoclonal antibodies (3B9)
were obtained from Abmart. Anti-Myc tagged mouse monoclonal
antibodies (9E10) were obtained from Beijing Protein Innovation
Company. Anti-HCV NS3 mouse monoclonal antibodies were
purchased from the Millipore Company. Anti-GFP rabbit
polyclonal antibodies were bought from the Proteintech Group.
Horseradish peroxidase (HRP) conjugated streptavidin (SA-HRP)
was obtained from CWBio.
DNA transfection
HEK293 cells were plated at approximately 2.5610
5 cell/well in
24-well plates and grown overnight to obtain 70–80% confluent
monolayer cells. DNA plasmids (0.2–0.5 mg) were transfected using
the Lipofectamine 2000 transfection reagent according to the
manufacturer’s protocol. Briefly, Opti-MEM I (50 ml) and Lipo-
fectamine2000 (1.5 ml) were incubated for 5 m at room tempera-
ture. DNA (0.2–0.5 mg) was added to the mixture and incubated for
an additional 20 m. After the medium was removed from the 24-
well plate, the DNA mixture and Opti-MEM I (250 ml) were then
added to each well and incubated at 37uC for 4 h. Subsequently,
complete growth DMEM (1 ml) was added to the mixture.
Transfected cells were then incubated for 24–72 h in the media
(1.3 ml). The cells were then processed to be used in assays.
Western blot
The cell lysate in RIPA buffer was resuspended with sample
loading buffer, boiled for 15 m and centrifuged at 12,000 rpm for
Table 1. Primers and other DNA sequences used in the experiment.
Name Sequences (59-39) Product size (bp)
BirA SacII F GCCCGCGGATGAAGGATAACACCGTGCCA 980
BirA NotI R GCGCGGCCGCTTATTTTTCTGCACTACGCA
IRES SalI SmaI F TCGTCGACTGACCCGGGAATTCCGCCCCTCTCCCTCCCCC 606
IRES SacII R TCCCGCGGTTATCATCGTGTTTTTCAAAGGA
NheI HAVI XhoI F CTAGCATGCATCATCACCATCACCACGGCTTGAACGACATCTTCGAGGCCCAGAAGATCGAGTGGCACGAGC
NheI HAVI XhoI R TCGAGCTCGTGCCACTCGATCTTCTGGGCCTCGAAGATGTCGTTCAAGCCGTGGTGATGGTGATGATGCATG
Fluc SalI F TCGTCGACATGGAAGACGCCAAAAACATAAA 1678
Fluc XhoI R CGCTCGAGAGATCCAGAGCCCACGGCGATCTTTCCGCCCTT
Rluc NheI F AG GCTAGCATGACTTCGAAAGTTTATGAT 951
Rluc XhoI R AGCTCGAGTTGTTCATTTTTGAGAACTCGCT
SalIFlagNotIF TCGACGATTACAAGGACGATGACGATAAGTGA
SalIFlagNotIR GGCCGCTCACTTATCGTCATCGTCCTTGTAATCG
MAVS XhoI F GCCTCGAGATGCCGTTTGCTGAAGACAAGA 1636
MAVS MluI R TCACGCGTGTGCAGACGCCGCCGGTACAGCA
MAVS CARD MluI R TCACGCGTACGGTCCGAGGTCCGAGGCT 322
MAVS PD XhoI F GCCTCGAGATGCCCCCAGACCCACTGGAGCCA 1252
MAVS PD MluI R TCACGCGTAGGTGAGGGCCTGTGGCATGG
MluI - MAVSTM- SalI F CGCGTGGGGCTCTGTGGCTCCAGGTGGCTGTGACAGGGGTGCTGGTAGTCACACTCCTGGTGGTGCTGTACG
MluI- MAVSTM-Sal R TCGACGTACAGCACCACCAGGAGTGTGACTACCAGCACCCCTGTCACAGCCACCTGGAGCCACAGAGCCCCA
TRAF3 XhoI F GCCTCGAGATGGAGTCGAGTAAAAAGATGG 1720
TRAF3 MluI R TCACGCGTGGGATCGGGCAGATCCGAAG
IRF3 XhoI F GCCTCGAGATGGGAACCCCAAAGCCACGGA 1297
IRF3 MluI R TCACGCGTGCTCTCCCCAGGGCCCTGGAAA
doi:10.1371/journal.pone.0026414.t001
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separated by SDS-PAGE gel and transferred onto a PVDF
membrane. The membranes were blocked with 3% BSA for
biotinylation protein detection or with 3% slim nonfat milk in PBS
containing 1.5% Tween 20 and then processed for immunodetec-
tion using the following antibodies: Myc, Flag, GFP, HCV NS3,
and HRP conjugated anti-mouse or anti-rabbit secondary
antibody (CWBio) or using SA-HRP for the detection of
biotinylation protein. Protein bands were visualized by adding
HRP membrane substrate (Millipore) and then scanned using the
ChemiDoc XRS System (Bio-Rad Universal Hood II).
Reporter assay
Cells (2.5610
5 per well in 24-well plates) were cotransfected
with expression plasmid DNA (0.1–0.3 mg), Fluc reporter plasmid
(0.1 mg) and the internal control vector pRL-TK (0.1 mg) using
Lipofectamine 2000 transfection reagent according to the
manufacturer’s protocol. Twenty-four hours post-transfection,
the cells were collected, lysed with 50 ml 1x passive lysis buffer
and then subsequently assayed for luciferase activity in cell lysate
using the Dual Luciferase Reporter Assay System (Promega).
Biotinylated protein pull-down assay
HEK293 cells were collected from 6-well plates at 48–72 h post-
transfection, washed twice with phosphate-buffered saline (PBS) to
remove D-Biotin in the media and then lysed with 60–200 ml
RIPA buffer (150 mM NaCl, 50 mM Tris, pH 8.0, 1 mM EDTA,
1% Nonidet P-40, 0.1% SDS, 8340 protease inhibitors (Sigma,
1:1000)). Approximately 3/4 of the cell lysate was incubated with
SA-PMPs (100 to 200 ml) at 4uC for 1 h for binding, followed by 3
washes with RIPA, RIPA high-salt buffer (RIPA buffer with
500 mM NaCl) and RIPA buffer at room temperature. The
protein bound to the beads was eluted by boiling the beads for
15 min in RIPA buffer with 1x sample loading buffer. The eluted
protein was analyzed by Western blot.
DLR-PD
HEK293 cells were transfected with HAVI-Fluc tagged (100 ng)
and Rluc tagged (100 ng) protein expression vectors in 24-well
plates using the Lipofectamine 2000 transfection reagent. At 24–
48 h post-transfection, cells were collected, washed twice with PBS
to remove D-Biotin from the media and then lysed with 30 mlo f1
x passive lysis buffer (Promega). The Fluc and Rluc activities in the
cell lysate (2 ml) in PBS (50 ml) was measured using the DLR assay
system before pull-down. Prior to binding, SA-PMPs (20 ml) were
washed twice with PBS and resuspended in PBS buffer (50 ml).
Then, SA-PMPs were incubated with 2 to 5 ml of cell lysate (more
than 1.0E+06 relative light unit) in a 96-well white opaque plate
for 30 m to 1 h for binding at room temperature, followed by two
washes in PBS with 1% Nonidet P 40 and once with PBS buffer on
a magnetic stack. The supernatant of the beads was transferred to
another well, and SA-PMP beads were resuspended in PBS (50 ml)
for the DLR assay. The dual luciferase activity in the SA-PMP
beads, the supernatant of the beads and the cell lysate prior to the
binding of SA-PMPs was measured with the Dual Luciferase
Reporter Assay System using a Glomax 96 microplate luminom-
eter (Promega). The Rluc activity of beads bound to Fluc was
directly measured on the beads to determine the amounts of
interacting proteins that bound to the beads after pull down. The
percentage of Fluc and Rluc activity on the beads compared with
the cell lysate was calculated by dividing the values for the Fluc
and Rluc activity on the beads by the Fluc and Rluc activity in the
cell lysate. This percentage was used to identify the PPIs. The
relative amount of interacting proteins binding to the beads was
indicated as the Rluc/Fluc ratio on the beads, which was
calculated by dividing the value of Rluc activity on the beads by
the value of Fluc activity on the beads. The Rluc/Fluc ratio on the
beads was used to analyze the PPIs.
Statistical analysis
The data represent one of at least two independent assays. All of
the results are expressed as the mean and standard deviation of
triplicate or duplicate measurements. Student’s t-test was used to
analyze the data.
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